Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
INNOVATIVE VISION PRODUCTS, INC. Delaware Office: 3511 Silverside Road, Suite 105, County of New Castle, Delaware USA 19810 [email protected] Moscow Office: Ivanovskaya 20, Suite 74, Moscow 127434 Russia Tel/Fax: +7 095 977 2387 Innovative Vision Products Mark Babizhayev MA, PhD. Anti-cataract N-Acetylcarnosine Statement of Fact February 3rd 2004 To Whom It May Concern, For the record I wish to confirm that I am Mark Babizhayev PhD, MA, and that I, along with my team of fellow research scientists, made the discovery and carried out all of the now published, research over the last ten to eleven years for the application of N-Acetylcarnosine to address senile cataracts and related ocular disorders. I also wish to state that my company, Innovative Vision Products (IVP), is the holder of the world wide patents for the use of N-Acetylcarnosine to address senile cataracts. In addition to our 1993 European Union patent application, we have filed patent applications in the United States and additional countries around the globe. Publications: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=PubMed Firstly I wish to emphasize a very important point and that is that there are serious potential risks to ocular health with the long term application of any preparation used in the eye and therefore usage should always be carefully considered and monitored by patients and their physicians. As stated repeatedly in my publications there is a very fragile and highly specific balance of purity for this formulation that must be maintained to ensure the safe and effective use of N-Acetylcarnosine eye drops. Therefore, it must be clearly understood that it is only formulas made to this specific purity and methodology, the patented formulas, that have been proven in animal and human clinical trials to be efficacious and most importantly, safe in long-term use. Innovative Vision Products (IVP) is the patent holder and the only maker of the clinically proven NAcetylcarnosine formula. For public safety I established IVP to ensure that the highest quality of standards are maintained for formula production control. Unfortunately there are a few amoral companies, attempting to capitalize on this discovery, which are illicitly fabricating and touting inferior N-Acetylcarnosine for senile cataracts without the benefit of the specific purity level and methodology required to ensure efficacy and safety for eye use. A number of these deceptive companies are actually referencing my research, to promote their substandard product, thereby damaging my reputation. In addition some are attempting to make their products more attractive with the addition of vitamins such as vitamin A and E. These vitamins, while by themselves may be beneficial to the eye, on the other hand have branched hydrocarbon skeletons that inhibit the activity of N-Acetylcarnosine, particularly in the critical cornea and conjunctiva of the eye. More importantly combinations of vitamins and NAcetylcarnosine have not got any published clinical trials for either efficacy or safety. This could lead to damage of the eye surface with long term use, as was shown with L-Carnosine in our trials. Therefore as the publisher of much research on this subject I feel a responsibility to inform consumers of the fraudulent and dangerous products being promoted to the public. The good news is that there is a very simple way to determine if one is purchasing the safe, patented product formula, the following statement is provided on the eye-drop labels by our approved private label distributors, - “N-Acetylcarnosine Patented by Innovative Vision Products”. Finding this phrase ensures that you have the exact same formula and purity, of eye drop, that was proven safe in our clinical trials. To conclude, for public safety we shall be vigorously defending our patents and issuing injunctions against distributors of non-approved N-Acetylcarnosine anti-cataract eye-drops, furthermore we shall be seeking damages where appropriate. Sincerely, Mark Babizhayev MA, PhD [For more complete information please see: www.nacetylcarnosine.com ]